4D Molecular Therapeutics, Inc. (FDMT) intrinsic value & 10-year financials
4D Molecular Therapeutics, Inc. (FDMT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 51.8% a year to $85.2M, with an average return on invested capital of 3.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $12.14
- Market cap
- $703.3M
- Revenue (FY2025)
- $85.2M
- Revenue growth (8-yr CAGR)
- 51.8%
- ROIC (10-yr avg)
- 3.1%
- Free cash flow (FY2025)
- -$109.6M
FDMT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $85.2M | -$140.1M | -$2.42 | -$109.6M | -187.2% | -37.9% |
| FY2024 | $37.0K | -$160.9M | -$2.98 | -$138.4M | -507678.4% | -83.4% |
| FY2023 | $20.7M | -$100.8M | -$2.58 | -$78.6M | -544.6% | -85.9% |
| FY2022 | $3.1M | -$107.5M | -$3.32 | -$98.2M | -3516.5% | -58.9% |
| FY2021 | $18.0M | -$71.3M | -$2.57 | -$78.2M | -395.5% | -88.6% |
| FY2020 | $13.4M | -$56.7M | — | -$51.9M | -424.0% | 278.6% |
| FY2019 | $7.0M | -$49.3M | — | -$39.9M | -729.4% | 98.1% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
4D Molecular Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
4D Molecular Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -36.3% ROIC.
4D Molecular Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, 4D Molecular Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-80.38 per share.